ABSTRACT
In this chapter, we describe our improved and evolving techniques in palladium-103 (Theraseed®) brachytherapy for patients with stage T1 and T2 adenocarcinoma of the prostate. We began this system in 1991.1
With our technique, brachytherapy is an effective, low morbidity, cost effective treatment for adenocarcinoma of the prostate. While both iodine-125 (125I) and palladium103 (103Pd) have been used extensively over the last 14 years,2 our opinion is that 103Pd (Theraseed®) provides a more rapid initial dose and therefore may give better control of higher Gleason grade tumors. We have assessed and highly refined our methodology for 103Pd brachytherapy in patients with prostate cancer.
